Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization

Summary by Joplin Globe
VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to provide an update on its proprietary Cladribine sublingual thin-film drug reformulation…

5 Articles

Joplin GlobeJoplin Globe
+3 Reposted by 3 other sources
Center

BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization

VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to provide an update on its proprietary Cladribine sublingual thin-film drug reformulation…

Read Full Article
stocktitan.netstocktitan.net

Novel MS Drug Delivery Breakthrough: BioNxt's Sublingual Thin-Film Tech Heads to Critical Animal Study

BioNxt completes tech transfer for Cladribine sublingual film MS treatment, advancing to pig bioavailability study in Oct 2025. Human trials targeted for Q1 2026.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources lean Left
75% Left

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Monday, September 29, 2025.
Sources are mostly out of (0)

Similar News Topics

Vancouver, British Columbia icon

Vancouver, British Columbia

News
For You
SearchBlindspotLocal